Abstract
Calpain is a family of cytosolic cysteine proteases activated by calcium (1–5). There are two major isoforms, µ- and m-calpain, requiring low and high micromolar calcium for in vitro activity, respectively. Both µ- and m-calpain have a large catalytic subunit (80 kDa) and a small regulatory subunit (29 kDa). Both subunits contain EF-hand calcium-binding structures which control the proteolytic activity of the enzyme. Calpains are implicated in a number of pathological conditions, including stroke, myocardial ischemia and cataract, where intracellular calcium levels are elevated markedly (6). In cerebral ischemia, synaptic glutamate (excitotoxin) buildup leads to excessive activation of ionotropic N-methyl-D-aspartate NMDA- and AMPA/kainate-receptors (7–8). The resultant calcium influx triggers calpain activation. Calpain then degrades cytoskeletal proteins which leads to the loss of cell integrity and cell death (9). Several peptide calpain inhibitors (e.g., calpain inhibitor I (acetyl-Leu-Leu-Nle-H) and MDL28170 (carbobenzoxy-Val-Phe-H)) were found to have neuroprotective effects in various models of excitotoxicity and/or ischemia (10-12). However, these agents are nonselective and cross-inhibit other cysteine proteases. Thus, it is highly desirable to develop selective and potent calpain inhibitors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Murachi, T., 1989, Intracellular regulatory system involving calpain and calpastatin, Biochem. Int. 18: 263–294.
Melloni, E., and Pontremoli, S., 1989, The calpains, Trends Neurosci. 12: 438–444.
Wang, K.K.W., Villalobo, A. and Roufogalis, B.D., 1989, Calmodulin-binding proteins as calpain substrates, Biochem. J. 262: 693–706.
Croall, D.E., and Demartino, G.N., 1991, Calcium-activated neutral protease (calpain) system: structure, function, and regulation, Physiol. Reviews 71: 813–847.
Saido, TC, Sorimachi, H., and Suzuki, K., 1994, Calpain: new perspectives in molecular diversity and physiological-pathological involvement, FASEB J. 8: 814–822.
Wang, K.K.W., and Yuen P-w., 1994, Calpain inhibition: an overview of its therapeutic potentials, Trends Pharmacol. Sci. 15: 412–419.
Lipton, S.A., and Rosenberg, P.A., 1994, Excitatory amino acids as a final common pathway for neurologic disorders, New England J. Med. 330: 613–622.
Meldrum, B., and Garthwaite, J., 1990, Excitatory amino acid neurotoxicity and neurodegenerative disease, Trends Pharmacol. Sci. 11: 379–387.
Siman, R., and Noszek, J.C., 1988, Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo, Neuron 1: 279–287.
Arlinghaus, L., Mehdi, S., and Lee, K.S., 1991, Improved posthypoxic recovery with a membrane-permeable calpain inhibitor, Europ. J. Pharmacol. 209: 123–125.
Hong, S.-C, Goto, Y, Lanzino, G., Soleau, S., Kassell, N.F., and Lee, K.S., 1994, Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia, Stroke 25: 663–669.
Bartus, R.T., Baker, K.L., Heiser, A.D., Sawyer, S.D., Dean, R.L., Elliott, P.J., and Straub, J.A., 1994, Postischemic adminstration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage, J. Cereb. Blood Flow Metab. 14, 537–544.
Buroker Kilgore, M., and Wang, K.K.W., 1993, ACoomassie brilliant blue G250-based colorimetric assay for measuring activity of calpain and other proteases, Anal. Biochem. 208: 387–392.
Wang, K.K.W., Villalobo, A. and Roufogalis, B.D., 1988, Further characterization of the calpain-mediated proteolysis of the human erythrocyte plasma membrane Ca2+-ATPase, Arch. Biochem. Biophys. 260: 696–704.
Emori, Y, Ohno, S., Tobita, M., and Suzuki, K., 1986, Gene structure of calcium-dependent protease retains the ancestral organization of the calcium-binding protein gene, FEBS lett. 194: 249–252.
Heussen, C, and Dowdle, E.B., 1980, Electrophoretic analysis of plasminogen activators in Polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102: 196–202.
Saido, T.C., Shibata, M., Takenawa, T, Murofushi, H., and Suzuki, K., 1992, Positive regulation of mu-calpain action by polyphosphoinositides, J. Biol. Chem. 267: 24585–24590.
Weber, M.L., Probert, A.W., Dominick, M.A., and Marcoux, F.W., 1993, Early ultrastructural injury in neuronal cell culture after hypoxia or combined oxygen and glucose deprivation: neuroprotection with 4-(3-phosphonopropyl)-2-piperazinecarboxylic acid (CPP), Neurodegeneration 2: 63–72.
Marcoux, EW., Probert, A.W., and Weber, M.L., 1990, Hypoxic neuronal injury in tissue culture is associated with delayed calcium accumulation, Stroke 21 (Suppl. Ill): 71–74.
Koh, J.Y, and Choi, D.D., 1987, Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay, J. Neurosci. Methods 20: 83–90.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Plenum Press, New York
About this chapter
Cite this chapter
Wang, K.K.W. et al. (1996). Alpha-Mercaptoacrylic Acid Derivatives as Novel Selective Calpain Inhibitors. In: Suzuki, K., Bond, J.S. (eds) Intracellular Protein Catabolism. Advances in Experimental Medicine and Biology, vol 389. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0335-0_11
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0335-0_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8003-0
Online ISBN: 978-1-4613-0335-0
eBook Packages: Springer Book Archive